HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib

HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib

From Oncology Data Advisor by i3 Health

April 3, 2026 · 6 min

About this episode

The episode discusses the expanded approval of zongertinib for treating HER2-mutant non-small cell lung cancer and its clinical implications.

Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.

People in this episode

Guest: Beth Sandy

Topics covered

  • HER2 mutations
  • non-small cell lung cancer
  • zongertinib
  • FDA approval
  • treatment landscape
  • oncology

Keywords

  • HER2
  • NSCLC
  • zongertinib
  • FDA approval
  • oncology
  • treatment
  • cancer

Mentioned in this episode

Organizations: University of Pennsylvania

Products: zongertinib

Places: FDA, non-small cell lung cancer, non-squamous NSCLC, HER2

More episodes of Oncology Data Advisor

Explore listener stats, chart rankings, contacts and more on the Oncology Data Advisor podcast page.